Skip to content
Tygacil(tigecycline)
Tygacil (tigecycline) is a small molecule pharmaceutical. Tigecycline was first approved as Tygacil on 2005-06-15. It is used to treat bacteremia, bacterial infections, bacterial pneumonia, bacterial skin diseases, and bacteroides infections amongst others in the USA. It has been approved in Europe to treat bacterial infections, bacterial skin diseases, infectious skin diseases, intraabdominal infections, and soft tissue infections.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
respiratory tract diseasesD012140
skin and connective tissue diseasesD017437
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Tygacil (generic drugs available since 2015-05-27)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Tigecycline
Tradename
Company
Number
Date
Products
TIGECYCLINEACCORD HLTHCARE INCN-208744 RX2018-01-18
1 products
TIGECYCLINEAmneal PharmaceuticalsN-211158 RX2018-08-02
1 products
TIGECYCLINEFresenius KabiN-205645 RX2016-12-01
1 products, RLD, RS
TYGACILCV SciencesN-021821 RX2005-06-15
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
tygacilNew Drug Application2023-04-20
tygacilNew Drug Application2023-04-20
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
bacteremiaEFO_0003033D016470R78.81
bacterial infections—D001424A49
bacterial pneumoniaEFO_1001272D018410J15.9
bacterial skin diseases—D017192—
bacteroides infectionsEFO_1000832D001442—
clostridium infectionsEFO_1000874D003015A05.2
escherichia coli infectionsEFO_1001318D004927B96.20
haemophilus infectionsEFO_1001127D006192—
intraabdominal infections—D059413—
klebsiella infectionsEFO_1001353D007710—
Show 3 more
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Tigecycline, Tigecycline, Amneal
98553352033-04-07DP
Tigecycline, Tygacil, Pf Prism Cv
83729952030-10-08DP
78798282029-02-05DP
89752422028-10-24DP
92543282026-03-13DP
96940782026-03-13DP
105889752026-03-13DP
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01A: Tetracycline antibiotics
— J01AA: Tetracyclines
— J01AA12: Tigecycline
HCPCS
Code
Description
J3243
Injection, tigecycline, 1 mg
Clinical
Clinical Trials
55 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Intraabdominal infectionsD059413—12249
Infectious skin diseasesD012874—11125
Cross infectionD003428——31—4
AppendicitisD001064EFO_0007149K37———213
PeritonitisD010538EFO_0008588K65———213
Abdominal abscessD018784EFO_1001753——12—3
Bacterial skin diseasesD017192—2—1—3
CholecystitisD002764HP_0001082K81———2—2
DiverticulitisD004238EFO_1001460K57———2—2
Catheter-related infectionsD0554991——1—2
Show 3 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Bacterial pneumoniaD018410EFO_1001272J15.9—25——7
Bacterial infectionsD001424A49—12—25
InfectionsD007239EFO_0000544——2—13
Community-acquired infectionsD017714——2—13
Lung diseasesD008171EFO_0003818J98.4—21——2
Gram-positive bacterial infectionsD016908——2——2
Skin diseasesD012871L00-L99——1——1
Ventilator-associated pneumoniaD053717EFO_1001865J95.851——1——1
Urinary tract infectionsD014552EFO_0003103N39.0——1——1
PyelonephritisD011704EFO_1001141N10-N16——1——1
Show 7 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Staphylococcal skin infectionsD013207EFO_1001849L00—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—2————2
Chronic kidney failureD007676EFO_0003884N18.61————1
Myeloid leukemia acuteD015470C92.01————1
Biliary liver cirrhosisD008105K74.31————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Acinetobacter infectionsD000151EFO_1000792————11
Soft tissue infectionsD018461————11
Critical illnessD016638————11
DiarrheaD003967HP_0002014R19.7————11
Clostridioides difficileD016360NCBITaxon_1496————11
Communicable diseasesD003141————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTIGECYCLINE
INNtigecycline
Description
Tigecycline, sold under the brand name Tygacil, is an tetracycline antibiotic medication for a number of bacterial infections. It is a glycylcycline administered intravenously. It was developed in response to the growing rate of antibiotic resistant bacteria such as Staphylococcus aureus, Acinetobacter baumannii, and E. coli. As a tetracycline derivative antibiotic, its structural modifications has expanded its therapeutic activity to include Gram-positive and Gram-negative organisms, including those of multi-drug resistance.
Classification
Small molecule
Drug classantibiotics (tetracycline derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CN(C)c1cc(NC(=O)CNC(C)(C)C)c(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O
Identifiers
PDB—
CAS-ID220620-09-7
RxCUI384455
ChEMBL IDCHEMBL376140
ChEBI ID149836
PubChem CID5282044
DrugBankDB00560
UNII ID70JE2N95KR (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Tygacil - Pfizer
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 14,565 documents
View more details
Safety
Black-box Warning
Black-box warning for: Tygacil, Tygacil
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
22,057 adverse events reported
View more details